Your session is about to expire
← Back to Search
Virus Therapy
Mitoquinone/mitoquinol mesylate for Coronavirus
Phase 1 & 2
Waitlist Available
Led By Theodoros Kelesidis, MD PHD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if the Mito-MES dietary supplement can prevent severe symptoms in adults exposed to respiratory viruses like COVID-19. The supplement may help the body fight off severe symptoms.
Eligible Conditions
- Coronavirus
- Viral Respiratory Infection
- Antiviral Treatment
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Viral Illness
Severity Score of Symptoms of Viral Illness
Secondary study objectives
Incidence of Treatment-Emergent Adverse Events as Assessed by the Proportion of Participants Exhibiting Adverse Events of Any Grade
Number of Participants With Any Symptoms of Viral Illness
Number of Participants With Fever
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: MitoQExperimental Treatment1 Intervention
Treatment group
Group II: Control groupActive Control1 Intervention
Control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitoquinone/mitoquinol mesylate
2022
Completed Phase 2
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
University of Texas Southwestern Medical CenterLead Sponsor
1,083 Previous Clinical Trials
1,058,609 Total Patients Enrolled
University of California, Los AngelesLead Sponsor
1,566 Previous Clinical Trials
10,263,374 Total Patients Enrolled
Theodoros Kelesidis, MD PHDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger